Remove tag eu-market-access
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Centralised incentives are also in place across Europe, as well as at the national level in some EU states. Go-to-market strategies. Efforts have been made to change this.

Drugs 147
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. In the US, the world’s largest pharmaceutical market, most states have legalized cannabinoids for medical use. This is closely followed by CB2 receptors in second place.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Anti-Counterfeiting Technologies in Healthcare

Roots Analysis

Examples of such technologies include DNA Taggants (a unique DNA tag used in the product / packaging that can be scanned using a designated instrument / equipment), invisible printing technologies, digital watermark technologies and hidden markers / print technologies.

article thumbnail

NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta

pharmaphorum

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year. billion by 2028. billion in sales in 2028.

Sales 109
article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution that works for everyone. Balancing the incentivisation of innovation against affordable access to revolutionary new medicines is an age-old conundrum in the biopharmaceutical industry.

article thumbnail

Bluebird’s $2.8M Gene Therapy Zynteglo Wins Landmark FDA Approval for Beta Thalassemia

XTalks

XTALKS WEBINAR: How Agile Clinical Trials Unlock Universal Access to Rare Disease Research. Zynteglo’s hefty price tag of $2.8 Live and On-Demand: Tuesday, October 4, 2022, at 11am EDT (4pm BST/UK). Although the therapy is administered to the patient once, the treatment process has several steps that may take place over several months.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. in December 2019; and.